Advanance Secures Series B After Successful Test

Adnavance Technologies, a molecular diagnostic company, secured $1.8 million in Series B funding from its current investors, which include GrowthWorks Working Opportunity Fund, Canadian Medical Discoveries Fund and Business Development Bank of Canada. The funding was triggered when the business's diagnostic test succeeded in distinguishing between MRSA and non-MRSA. Adnavance is headquartered in Vancouver, British Columbia. Company Web site